News

VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Dr. Banerjee previously served as Vice President & Disease Area Head, Rheumatology and Dermatology at Bristol Myers SquibbBRIDGEWATER, N.J., July…

1 year ago

Curonix Receives the First Full-Body Peripheral Nerve Stimulator (PNS) FDA Clearance, including Craniofacial Pain Indication, for its Freedom® PNS System

POMPANO BEACH, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Curonix LLC, a medical technology company dedicated to relieving chronic pain…

1 year ago

Smith+Nephew is trailblazing a new path for female surgeons with its Orthopaedics for All initiative; a first-of-its-kind global advisory board

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company announces its Orthopaedics for All initiative – a global advisory board established…

1 year ago

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing…

1 year ago

AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450

– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the…

1 year ago

ZyVersa Therapeutics’ CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024

ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Phase 2a…

1 year ago

Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Oral Antipsychotic

-Statistically significant benefit demonstrated in primary endpoint of positive subscale of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS)…

1 year ago

Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan

GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving…

1 year ago

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because…

1 year ago

DAS Health Expands Into Canadian Market with Recent Acquisition

Tampa, July 09, 2024 (GLOBE NEWSWIRE) -- DAS Health Ventures, LLC (DAS Health), a provider of healthcare IT and business…

1 year ago